What we do Syngene International Ltd offers integrated research, development, and manufacturing services to global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. |
Founded in 1,993 |
Market share Among India’s largest integrated CRDMOs, serving 14 of top 20 global pharma companies, with expanding global footprint. |
Problem solved Accelerates innovation by providing end-to-end scientific services reducing time-to-market and development costs for drug discovery and manufacturing. |
Top clients or who we serve Clients include global pharma, biotech, animal health, nutrition, and specialty chemical firms; business-to-business (B2B) model. |
Key management Peter Bains (MD & CEO), Deepak Jain (CFO) - experienced leaders driving global growth and innovation. |
Our journey and innovations Founded in 1993; pioneered integrated CRO/CDMO services; expanded research and manufacturing; acquired biologics facilities (including USA); launched advanced platforms like SynVent and Syn.AI. |
Where we operate Operations across India (Bangalore, Hyderabad, Mangalore) and USA (Baltimore); serving clients worldwide including US, Europe, and Japan. |
Top products or what we offer Discovery services, drug development, small and large molecule manufacturing, clinically compliant biologics production, dedicated R&D centers. |
Top brands Key platforms include SynVent™ integrated drug discovery, SARchitect data analytics, SynTIPS and Syn.AI for therapeutic R&D enhancement. |
Raw materials needed Chemicals, cell lines, bioreagents, specialized compounds for pharmaceutical and biologic product development. |
Raw materials supplier Global suppliers network including Indian ecosystem; supply chain diversified to reduce China dependence. |
Recurring vs cyclical contribution Revenue mainly recurring from long-term collaborations and dedicated centers; supplemented by project-based services. |
Our industry position Leader in Indian CRDMO sector; expanding biologics manufacturing and integrated drug discovery capabilities, ranked top in sustainable growth. |
Financial highlights FY25 revenue Rs. 3642 crore with Rs. 496 crore net profit; steady growth with strategic biologics expansion and global acquisitions. |
Geographical revenue split FY25 revenues primarily from USA (over 60%), Europe (~30%), India and Rest of World (balance). |
Order book Robust order book backed by long-term contracts with pharma giants like BMS, Amgen, and Zoetis. |
Whats driving growth Growth driven by biologics manufacturing capacity expansion, advanced platforms, global partnerships, and innovation investments. |
Our future plans Expanding biologics footprint, new R&D centers, capacity scaling in India and USA, and enhanced AI-driven drug discovery platforms. |
Our green promise Energy sourced 92% renewably; strong environmental management; extensive waste recycling and water conservation initiatives. |
Our people and values Over 8,200 employees with more than 5,600 scientists; culture centered on innovation, inclusion, and continuous development. |
Key challenges ahead Managing complex projects, maintaining growth amid global competition, supply chain risks and regulatory compliance. |
Interesting facts Only pharma/biotech in India awarded 5S certification for lab excellence; ranked #1 in India for sustainable growth globally. |
Risks and strategy Mitigates industry risks through enterprise risk management, supply diversification, and continuous operational excellence efforts. |
